Description

Tirzepatide is supplied as a sterile, lyophilized powder in 5mg×10 vials. Each lot is synthesized via solid-phase peptide synthesis (SPPS), purified by reversed-phase HPLC, and characterized by mass spectrometry to confirm sequence integrity.

Specifications

• Catalog #: HP-TR5
• Presentation: 5mg×10 vials
• Purity: ≥ 99% (HPLC)
• Identity: Confirmed by ESI-MS
• Endotoxin: < 1 EU/mg (LAL)
• Storage: 2–8 °C lyophilized; reconstituted aliquots at −20 °C

Quality control

Every batch ships with a Certificate of Analysis (COA) listing HPLC chromatogram, mass-spec confirmation, residual-solvent screen, and bioburden / endotoxin results. COAs are matched to lot numbers printed on each vial.

Research use only

This material is sold strictly for in vitro laboratory research and analytical reference use. It is not a drug, food, cosmetic, or dietary supplement, and is not intended for human or veterinary diagnostic or therapeutic use. By purchasing you agree to handle the material in accordance with your institution’s safety protocols and applicable local regulations.